Advancing new drug therapies for unmet medical needs

Developing novel drug therapies for unmet medical needs 2018-11-14T18:17:53+00:00

The Dimerix Limited Clinical Trials – ACTION for Diabetic Kidney Disease and ACTION for Focal Segmental Glomerulosclerosis – Are Now Open!

Click Here For More Information

Dimerix Limited is a clinical stage biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB)

Our vision is to positively improve human health by creating safe and effective new treatments for patients with unmet medical needs

Research

Our lead program DMX-200 is advancing through Phase 2 trials in patients with Chronic Kidney Disease (CKD).

Learn More

Technology

Our Receptor Heteromer Investigation Technology (Receptor-HIT) has been used by global pharmaceutical partners, and supported the development of our own DMX-200 program.

Learn More

Investors

Access the latest company news and information

Visit Investor Centre

Recent news and media

Analyst Coverage: Dimerix Appears on Bulls, Bears and Brokers series

https://youtu.be/G2n87j7lu3U   Dimerix is mentioned by Tony Locantro at 7:17.

ASX: DIMERIX RECEIVES R&D TAX CASH REBATE TOTALLING $1.07 MILLION

Read more here.

ASX: Dimerix Awarded $50,000 Innovation Connections Grant

More information available here

Click here to view analyst coverage
Click here to view our corporate fact sheet
Click here to view our corporate presentation

Home
Company
Program
Technology
Investors
Contact

© Copyright 2019 Dimerix | Credits

subscribe to patient updates

subscribe to news updates